Literature DB >> 1824556

Effect of differential tracer washout during SPECT acquisition.

J M Links1, T L Frank, L C Becker.   

Abstract

A central assumption in SPECT is that the projection data are "consistent," that is, the camera views an unchanging distribution during acquisition. Several new radiotracers of interest, including 99mTc-teboroxime (Cardiotec), have rapid clearance from the myocardium. Furthermore, the washout is different in normal and ischemic tissues. We used computer simulations to estimate the effect of this differential washout on quantification of the severity of ischemia. We simulated defect-to-normal myocardial activity ratios of 1 (no defect), 0.8, 0.6, 0.4, 0.2, and 0 (complete defect), with single defects placed either in the lateral wall or apex, and SPECT acquisitions of 1, 3, 6, 12, and 24 total minutes. We modeled washout with a monoexponential curve whose clearance half-time was 5.9 min for "normal myocardium" and 9.3 min for "ischemic myocardium." We found that differential washout from normal and ischemic zones produced image artifacts and errors in defect quantification for acquisitions longer than 3 min. With longer acquisitions, the degree of ischemia was significantly underestimated, with increasing error at longer acquisition times. In addition, in the "no defect" situation an apparent small lateral wall defect (relative to the apex) was present. Finally, lateral wall defects produced artifacts (streaks and reduced apparent activity) in the opposite (medial) wall. Differential normal/ischemic zone washout during SPECT acquisition produces artifacts and errors in quantification, whose severity is dependent on acquisition length, actual defect severity, and defect location.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824556

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Analytical propagation of errors in dynamic SPECT: estimators, degrading factors, bias and noise.

Authors:  D J Kadrmas; E V DiBella; R H Huesman; G T Gullberg
Journal:  Phys Med Biol       Date:  1999-08       Impact factor: 3.609

2.  4D maximum a posteriori reconstruction in dynamic SPECT using a compartmental model-based prior.

Authors:  D J Kadrmas; G T Gullberg
Journal:  Phys Med Biol       Date:  2001-05       Impact factor: 3.609

3.  C-SPECT - a Clinical Cardiac SPECT/Tct Platform: Design Concepts and Performance Potential.

Authors:  Wei Chang; Caesar E Ordonez; Haoning Liang; Yusheng Li; Jingai Liu
Journal:  IEEE Trans Nucl Sci       Date:  2009-10-06       Impact factor: 1.679

Review 4.  What is the current status of quantification and nuclear medicine in cardiology?

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1996-07

5.  Technetium 99m-labeled teboroxime: death in utero, infanticide, or failure to thrive?

Authors:  R J Burns
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

Review 6.  Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?

Authors:  B Caner; G A Beller
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

Review 7.  Multidetector single-photon emission tomography: are two (or three or four) heads really better than one?

Authors:  J M Links
Journal:  Eur J Nucl Med       Date:  1993-05

8.  Optimal timing for initial and redistribution technetium 99m-N-NOET image acquisition.

Authors:  F D Petruzella; M Ruiz; P Katsiyiannis; D D Watson; R Pasqualini; G A Beller; D K Glover
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

9.  Detection of coronary artery disease by dynamic planar and single photon emission tomographic imaging with technetium-99m teboroxime.

Authors:  H Yamagami; Y Ishida; T Morozumi; T Kozuka; T Nishimura
Journal:  Eur J Nucl Med       Date:  1994-01

10.  Static Versus Dynamic Teboroxime Myocardial Perfusion SPECT in Canines.

Authors:  D J Kadrmas; E V R Di Bella; H S Khare; P E Christian; G T Gullberg
Journal:  IEEE Trans Nucl Sci       Date:  2000-06-01       Impact factor: 1.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.